ClinicalTrials.gg
Status unknownNCT04174456Updated Aug 26, 2020

Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy

An interventional study of FDG PET in Dilated Cardiomyopathy, sponsored by Dong-A University. Status unknown at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-26.

Sponsored by Dong-A University · Not applicable, Interventional, and Other

How we know

The sponsor has not verified this record recently (last verified Aug 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study proceeds with prospective, randomized, open and controlled clinical trials. The subject of the investigator's study was the first patient diagnosed with dilated cardiomyopathy. Subjects who agreed to participate in the study and were determined to meet the selection / exclusion criteria were randomly assigned to each group, and the experimental group was treated with 20 mg of olmesartan and 5 mg of rosuvastatin for 6 months, and the control group is treated with 40 mg of valsartan and 5 mg of rosuvastatin.

Read the detailed description

Myocardial viability plays an important role in improving the function of the heart. To date, the most reproducible and objective method has been established as a method or tool for assessing myocardial viability.

Olmesartan is known to have the strongest inhibitory ability of angiotensin receptors compared with other angiotensin receptor binding inhibitors. Research has been reported that statin drugs may help improve vascular endothelial function, and several researchers have suggested that these mechanisms may affect the improvement of myocardial survival. In addition, studies have shown that angiotensin receptor binding inhibitors and statins may improve left ventricular function in patients with left ventricular function. However, since the studies did not assess myocardial survival, the mechanisms could not be clearly identified.

The purpose of this study is to investigate the effect of olmesartan on myocardial survival in patients with dilated cardiomyopathy who have left ventricular dysfunction.

02

Conditions studied

  • Dilated Cardiomyopathy
03

In context

Cardiomyopathy, Dilated

256 studies on the registry are indexed under Cardiomyopathy, Dilated; 67 are open to participants now.

This study's planned enrollment of 40 is close to the median of 43 across 145 interventional studies indexed under Cardiomyopathy, Dilated.

Browse Cardiomyopathy, Dilated studies →

Lead sponsor

Dong-A University is the lead sponsor of 33 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • dilated cardiomyopathy

Exclusion criteria

Exclusion Criteria:

  • to angiotensin receptor blocker
  • cardiogenic shock
  • sensitive to rosuvastatin
  • liver cirrhosis more than Child class B
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Olmesartan group

    olmesartan 20mg once daily with rosuvastatin 5mg once a day for 6-month

    Diagnostic Test: FDG PET

  • Active comparator
    Valsartan group

    valsartan 40mg twice daily with rosuvastatin 5mg once a day for 6-month

    Diagnostic Test: FDG PET

Interventions

  • Diagnostic testFDG PET

    baseline and 6-month follow-up FDG PET

06

What researchers measure

Primary outcomes

  1. Rate of glucose metabolism

    data from fludeoxyglucose positron emission tomography

    Time frame: 6 month

07

Study locations

1 of 1 sites recruiting
  • Department of Internal Medicine,Dong-A University College of Medicine
    Busan, Korea, Republic of
    Recruiting
    • Kyungil Park, MD · Contactsotier@dau.ac.kr · 82-51-240-2733
    • Sua Jo, MD · Contactflysofina@gmail.com · 82-10-3900-9713
    • Chang-Bae Sohn, MD · Sub investigator
    • Jeonghwan Kim, MD · Sub investigator
    • Yong-Seop Kwon, MD, PhD · Sub investigator
    • Su Hong Kim, MD, PhD · Sub investigator
    • Kyungil Park, MD, PhD · Principal investigator
08

References and documents

Publications

  • Jo S, Moon H, Park K, Sohn CB, Kim J, Kwon YS, Kim SH. Design and rationale for a comparison study of Olmesartan and Valsartan On myocardial metabolism In patients with Dilated cardiomyopathy (OVOID) trial: study protocol for a randomized controlled trial. Trials. 2022 Jan 15;23(1):36. doi: 10.1186/s13063-021-05970-7. PubMed 35033178 ↗

Individual participant data

Plan to share: No — We don't have any plan to make individual participant data (IPD) available to other researchers

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Dec 2021, 24 months after the start.

Of 28 interventional studies with no phase under Cardiomyopathy, Dilated, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 73. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2019
First posted
Nov 22, 2019
StartActual
Dec 1, 2019
Primary completionEst.
Dec 1, 2021
CompletionEst.
Dec 31, 2021
Last update
Aug 26, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04174456
Lead sponsor
Dong-A University
Responsible party
Kyungil Park (Associate professor, Dong-A University) — Principal investigator
First posted
Nov 22, 2019
Start date
Dec 1, 2019
Primary completion
Dec 1, 2021 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
Aug 26, 2020

Study contacts

Kyung-Mi Ko
Contact
kkmcrc@naver.com
82-51-240-5740
Kyungil PARK
study director · Dong-A University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion